Answer
Vigabatrin passes into human breast milk, and because information about effects on newborns or infants is insufficient, a decision about stopping breast-feeding or stopping or avoiding Sabril therapy must weigh the child's breast-feeding benefit against the woman's treatment benefit.
Sources for this answer
- Sabril 500 mg granules for oral solutionSANOFI · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 12Document updated
Sources checked